Xencor (NASDAQ:XNCR) VP Sells $31,689.70 in Stock

Xencor, Inc. (NASDAQ:XNCR) VP John Desjarlais sold 2,663 shares of the stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $11.90, for a total value of $31,689.70. Following the sale, the vice president owned 270,451 shares of the company’s stock, valued at $3,218,366.90. This trade represents a 0.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Xencor Price Performance

Shares of NASDAQ XNCR traded up $0.72 during mid-day trading on Wednesday, reaching $12.74. The company had a trading volume of 704,223 shares, compared to its average volume of 590,924. The company has a 50-day moving average price of $12.96 and a two-hundred day moving average price of $12.91. The stock has a market cap of $934.35 million, a PE ratio of -10.27 and a beta of 0.95. The company has a current ratio of 6.25, a quick ratio of 6.25 and a debt-to-equity ratio of 0.12. Xencor, Inc. has a 1-year low of $6.92 and a 1-year high of $18.69.

Xencor (NASDAQ:XNCR) last announced its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.55. The business had revenue of $28.24 million during the quarter, compared to the consensus estimate of $29.97 million. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.Xencor’s revenue was down 46.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.62) earnings per share. On average, equities analysts anticipate that Xencor, Inc. will post -3.68 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on XNCR. JPMorgan Chase & Co. cut their target price on shares of Xencor from $20.00 to $18.00 and set an “overweight” rating on the stock in a research note on Thursday, November 6th. Cantor Fitzgerald increased their price objective on Xencor from $40.00 to $42.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a research report on Monday, December 29th. Wedbush reiterated an “outperform” rating and issued a $26.00 target price on shares of Xencor in a report on Thursday, November 6th. Finally, Barclays increased their price target on shares of Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $25.00.

Institutional Investors Weigh In On Xencor

Large investors have recently made changes to their positions in the company. AQR Capital Management LLC bought a new position in Xencor during the first quarter valued at approximately $438,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Xencor by 9.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,047 shares of the biopharmaceutical company’s stock worth $471,000 after purchasing an additional 3,692 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Xencor by 89.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 726,734 shares of the biopharmaceutical company’s stock worth $7,732,000 after purchasing an additional 344,088 shares during the last quarter. CWM LLC raised its holdings in shares of Xencor by 159.1% during the 2nd quarter. CWM LLC now owns 8,736 shares of the biopharmaceutical company’s stock valued at $69,000 after purchasing an additional 5,364 shares in the last quarter. Finally, AlphaQuest LLC lifted its stake in shares of Xencor by 144.0% in the 2nd quarter. AlphaQuest LLC now owns 12,946 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 7,641 shares during the last quarter.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.